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Objectives: To identify risk factors for failure of outpatient antibiotic therapy (OPAT) in infective endocarditis (IE).
Patients and methods: We identified IE cases managed at a single centre over 12 years from a prospectively
maintained database. ‘OPAT failure’ was defined as unplanned readmission or antibiotic switch due to adverse
drug reaction or antibiotic resistance. We analysed patient and disease-related risk factors for OPAT failure by
univariate and multivariate logistic regression. We also retrospectively collected follow-up data on adverse
disease outcome (defined as IE-related death or relapse) and performed Kaplan–Meier survival analysis up
to 36 months following OPAT.
Results: We identified 80 episodes of OPAT in IE. Failure occurred in 25/80 episodes (31.3%). On multivariate
analysis, cardiac or renal failure [pooled OR 7.39 (95% CI 1.84–29.66), P¼0.005] and teicoplanin therapy
[OR 8.69 (95% CI 2.01–37.47), P¼0.004] were independently associated with increased OPAT failure. OPAT
failure with teicoplanin occurred despite therapeutic plasma levels. OPAT failure predicted adverse disease
outcome up to 36 months (P¼0.016 log-rank test).
Conclusions: These data caution against selecting patients with endocarditis for OPAT in the presence of cardiac
or renal failure and suggest teicoplanin therapy may be associated with suboptimal OPAT outcomes. Alternative
regimens to teicoplanin in the OPAT setting should be further investigated.
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Introduction
Infective endocarditis (IE) is a serious and potentially life-
threatening infection that requires prolonged intravenous
therapy.1 Careful patient selection is necessary to identify
those suitable for outpatient parenteral antibiotic therapy
(OPAT).1,2 While avoiding OPAT entirely in patients with high-risk
features [e.g. left-sided valve disease, staphylococcal or entero-
coccal infection, and prosthetic valve endocarditis (PVE)] has
been recommended,1 several observational studies have
reported treating high-risk patients with OPAT.3 – 7 Although
these studies conclude that OPAT can be safely administered if
patients are carefully selected, there are limited data on the
factors associated with OPAT failure4 and it is unclear whether
features associated with adverse outcome in inpatients1 also
apply to the selected OPAT-managed population. We analysed
12 years of prospectively acquired clinical data on OPAT-
managed IE in a single centre to identify factors associated
with OPAT failure.
Methods
Setting
The Glasgow OPAT programme and its prospective database have been
described previously.8 Patient selection and individualized OPAT manage-
ment plans were the responsibility of the treating OPAT physician
(R. A. S.).8 Briefly, patients received up to 6 weeks of therapy for native
valve endocarditis and extended therapy for PVE. Ceftriaxone was used
first-line for susceptible streptococci and Staphylococcus aureus (in com-
bination with a second oral antibiotic), while teicoplanin plus a second
oral antibiotic was used first-line for infections with coagulase-negative
Staphylococcus, enterococci and methicillin-resistant S. aureus (MRSA),
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or those with a b-lactam antibiotic allergy. Teicoplanin dosing followed a
validated protocol9 with target trough levels ≥20 mg/L.10
Data collection
The local research ethics committee granted a waiver for this study and
the Caldicott guardian approved contact with general practitioners (GPs).
IE cases were defined according to modified Duke criteria.11 Clinical data
on demographics, comorbidities, organism, antibiotic regimen and
outcome were extracted from the prospective database.8 In parallel,
raw data were retrospectively reviewed (OPAT pro formas, case notes,
electronic clinical and laboratory databases and death certificates). In
cases without evidence of ongoing specialist review, GPs were tele-
phoned by a member of the study team (D. A. B.) to identify outcomes
of interest.
Outcomes
Failure to complete the initial OPAT regimen (OPAT failure) included any of:
(i) unplanned readmission or surgery during OPAT; (ii) adverse drug reac-
tion leading to switch/readmission; and (iii) development of antibiotic
resistance.
Adverse disease outcome (ADO) was assessed for each first patient-
episode, defined as IE-related death at any time or suspected relapse
at the same site after OPAT completion/failure. Episodes where OPAT
treatment was not intended to be curative (i.e. PVE where definitive
surgery was contraindicated/refused) or where cause of death could
not be determined were excluded from ADO analysis.
Statistical analysis
Continuous data were compared with the Mann–Whitney test. ORs for
OPAT failure were calculated for known risk factors selected before
data collection from inpatient studies. A multivariate logistic regression
model was constructed with backward stepwise selection of all variables
with P,0.05 on univariate analysis. A Kaplan–Meier survival analysis of
the influence of OPAT failure on ADO, censored at the date of the last
specialist review, date of event or 36 months from OPAT discharge
(whichever was sooner), was also performed. Two-tailed alpha ,0.05
was considered significant. Analysis was done using MedCalcw version
11.6.1.0.
Results
Inclusion
Ninety-seven episodes of OPAT in IE were identified from August
2000 to September 2012. Sixteen of 97 episodes were classified
‘not IE’ by modified Duke criteria and 1 of 97 did not require par-
enteral treatment (Q fever). Therefore 80 episodes in 77 patients
were included in the analysis: 67 were ‘definite’ or ‘possible’ IE, 4
were cardiac-device-related IE and 9 had incomplete informa-
tion to fully apply modified Duke criteria, but were included
based on strong supporting clinical and/or microbiological evi-
dence for IE.2 The median duration of OPAT was 28 days (IQR
20–38 days) and all patients had a prior period of inpatient
management (median 22 days, IQR 14–30 days).
Characteristics
High-risk features were common in the cohort: 65/80 (81.3%)
episodes were left-sided and 26/80 (32.5%) involved a prosthetic
valve. Staphylococci or enterococci were the cause of 30/80
episodes (37.5%) and planned surgery was done in 22/80
(27.5%). Septic emboli occurred pre-OPAT in 13/80 episodes
(16.3%). An established prior medical history of comorbidity (in-
cluding chronic kidney disease, ischaemic heart disease, chronic
heart failure, adult congenital heart disease, active cancer and
diabetes) was present prior to OPAT in 42/77 patients (54.5%;
see Table 1).
OPAT failure
OPAT failure occurred in 25/80 (31.3%) episodes based on the
composite endpoint definition (where more than one factor
could apply per episode). These included readmission (OPAT/IE
related, 9; unrelated, 10; and unknown, 2), adverse drug (7) or
line (3) events and resistance (2). Risk factors for OPAT failure
are summarized in Table 1.
ADO
Six episodes were excluded from ADO analysis (three repeat-
patient episodes, one death of undetermined cause and two epi-
sodes where curative treatment was contraindicated). Eight of
74 episodes of ADO occurred during a median of 729 days of
follow-up (range 35–3838 days); 7/8 were suspected relapses,
at a median of 77 days (range 35–780 days) post-OPAT, and 2
of the patients died. An additional patient died of post-operative
complications 47 days after unplanned readmission for surgery.
OPAT failure was significantly associated with ADO by survival
analysis (P¼0.016 log-rank test; Figure 1).
Univariate analysis
Several factors were associated with the risk of OPAT failure
(Table 1). An increased probability of failure was associated
with comorbidities (cardiac or renal failure), presence of an intra-
vascular device, PVE, glycopeptide-indicated organism and
factors relating to the quality of pre-OPAT management (e.g.
delay in starting inpatient antibiotics). Teicoplanin was asso-
ciated with OPAT failure in 12/18 courses (with a total of 17 cri-
teria for failure). Reasons for failure were readmissions [7/17 due
to suspected endocarditis decompensation—clinical cardiac dys-
function or new fever—treated medically (5) or surgically (2); 4/
17 non-IE related; and 1/17 unknown], adverse drug reactions
leading to switch/readmission [4/17: hyperkalaemia (1); vomiting
due to co-administered pristinamycin (1); acute renal dysfunc-
tion (1); and presyncope during antibiotic administration (1)]
and resistance to the oral antibiotic component of the OPAT
regimen (1/17)—in some cases several criteria for failure oc-
curred in the same episode. In contrast, ceftriaxone, streptococ-
cal IE and specialist inpatient management prior to OPAT (i.e. by
infectious diseases or cardiology) were associated with OPAT
completion.
Multivariate analysis
Cardiac or renal failure was independently associated with
increased OPAT failure [pooled OR 7.39 (95% CI 1.84–29.66),
P¼0.005] as was teicoplanin use [OR 8.69 (95% CI 2.01–
37.47), P¼0.004; Table 1]. Sensitivity analysis controlling for
the presence of any subtherapeutic teicoplanin concentration
OPAT failure with teicoplanin
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(,20 mg/L) did not affect the results of the multivariate analysis
(data not shown). In addition, there was no significant difference
in the median OPAT teicoplanin trough level in those who failed
or completed OPAT [28.6 mg/L (range 16.3–40.0 mg/L) versus
34.2 mg/L (range 28.3–52.7 mg/L), P¼0.070 Mann–Whitney
test].
Discussion
We devised a broad definition of ‘OPAT failure’ for patients with
endocarditis in order to identify patient and treatment factors
associated with failure to successfully complete a course of
OPAT. This composite endpoint included unplanned readmission
or surgery during OPAT, adverse drug reaction leading to a
switch in antimicrobial therapy or readmission, or development
of antibiotic resistance. We have previously used this approach
to identify factors associated with OPAT failure for other infec-
tions,8,12 and it is supported by recently published OPAT good
practice recommendations.13
Teicoplanin has been used in European OPAT programmes for
several years due to its favourable pharmacokinetic properties,
which permit once-daily or thrice-weekly dosing schedules.9 Con-
cerns have been raised about the comparative efficacy of teico-
planin against vancomycin, but a recent meta-analysis showed
equivalent efficacy.14 Although teicoplanin is currently recom-
mended for inpatient or OPAT IE management,10 few data
are available directly comparing glycopeptides with other
Table 1. Risk factors for OPAT failure
Factor
Failed, n¼25
(31.3%)
Completed,
n¼55 (68.7%)
Univariate analysis Multivariate analysis
OR CI P OR CI P
Comorbidity (CHF or CKD) 14 (63.6%) 8 (36.4%) 7.48 2.52–22.21 ,0.001 7.39 1.84–29.66 0.005
Teicoplanin 12 (67.7%) 6 (33.3%) 7.54 2.37–23.93 ,0.001 8.69 2.01–37.47 0.004
Specialist referral 17 (25.8%) 49 (74.2%) 0.26 0.08–0.86 0.027 0.25 0.06–1.11 0.068
Prosthetic valve 14 (53.8%) 12 (46.2%) 4.90 1.74–13.79 0.003 — — —
Median delay to intravenous start,
per day (IQR)
4 (0.5–13) 1 (0–3) 1.07 1.01–1.14 0.026 — — —
Glycopeptide-indicated organism 13 (46.4%) 15 (53.6%) 2.89 1.08–7.73 0.035 — — —
Intravascular device 8 (57.1%) 6 (42.9%) 3.56 1.08–11.68 0.037 — — —
Age, per yeara, median (IQR) 67.1 (55.3–72.2) 59.1 (51.0–68.0) 1.01 0.98–1.05 0.466 — — —
Male 15 (25.4%) 44 (74.6%) 0.38 0.13–1.06 0.064 — — —
Previous IE 4 (40.0%) 6 (60.0%) 1.56 0.40–6.01 0.526 — — —
Adult congenital heart disease 2 (28.6%) 5 (71.4%) 0.87 0.16–4.82 0.873 — — —
Ischaemic heart disease 11 (45.8%) 13 (54.2%) 2.54 0.93–6.94 0.069 — — —
CKD 7 (63.6%) 4 (36.4%) 4.96 1.30–18.95 0.019 — — —
CHF 9 (60.0%) 6 (40.0%) 4.59 1.42–14.91 0.011 — — —
Aortic valve 12 (35.3%) 22 (64.7%) 1.45 0.55–3.83 0.448 — — —
Left-sided 20 (30.8%) 45 (69.2%) 1.00 0.28–3.64 1.00 — — —
Emboli 3 (23.1%) 10 (76.9%) 0.64 0.16–2.58 0.533 — — —
S. aureus 4 (30.8%) 9 (69.2%) 0.97 0.27–3.52 0.9674 — — —
Streptococcalb 6 (17.6%) 28 (82.4%) 0.30 0.11–0.88 0.023 — — —
Enterococcal 3 (60.0%) 2 (40.0%) 3.61 0.56–23.14 0.175 — — —
Median inpatient stay, per day (IQR) 30 (21–37) 19 (12.5–32.5) 1.03 1.00–1.06 0.060 — — —
Median days of inpatient antibiotics (IQR) 26 (17–33) 17 (12–27) 1.02 0.98–1.06 0.314 — — —
Surgery during this episode 7 (31.8%) 15 (68.2%) 1.04 0.36–2.98 0.946 — — —
Unable to self-administer/home administer 13 (40.6%) 19 (59.4%) 2.05 0.78–5.37 0.143 — — —
Ceftriaxonec 8 (17.4%) 38 (82.6%) 0.22 0.08–0.66 0.004 — — —
Daptomycin 3 (27.3%) 8 (72.7%) 0.80 0.19–3.32 0.760 — — —
CHF, chronic heart failure; CKD, chronic kidney disease.
Percentages given are the relative percentages of each factor. Factors in bold were input into the logistic regression model with stepwise backwards
selection (x2¼30.3, full model 22 log likelihood¼63.6, P,0.0001); factors retained in the model (P,0.1) are displayed in the right-hand columns.
Intravascular device refers to permanent pacemakers and implantable defibrillators. Comorbidities refer to an established medical diagnosis prior to
OPAT. Patients with CKD had a median glomerular filtration rate of 22 mL/min (range 5–44 mL/min). Several non-significant factors in the univariate
analysis occurred in six or fewer episodes (alcohol misuse, diabetes, active cancer, cardiac-device-related endocarditis and flucloxacillin) and are not
displayed for clarity. Additional microbiological causes were coagulase-negative Staphylococcus (12), culture negative (8), mixed (3), Haemophilus,
Actinobacillus, Cardiobacterium, Eikinella and Kingella spp. (‘HACEK’) group (2), Rothia sp. (1), Gamella sp. (1) and unknown (1).
aP¼0.018, Mann–Whitney.
bCovariate with glycopeptide-indicated organism.
cCovariate with teicoplanin.
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treatments for IE. An open-label randomized controlled trial
(RCT) of daptomycin versus standard therapy for S. aureus bac-
teraemia and right-sided IE suggested equivalent efficacy15
and included some OPAT patients,5 but no comparative studies
have been done for other pathogens.
Teicoplanin has been associated with OPAT failure in skin and
soft-tissue infections8 and with a trend towards increased failure
in bone and joint infections.12 Its microbiological efficacy in
complex infections is related to drug concentration,9 and the
thrice-weekly dosing regimen used here has been shown to effi-
ciently achieve therapeutic levels in the OPAT setting.9 We
observed that the high rate of OPAT failure associated with teico-
planin use was independent of teicoplanin dosage and organism;
however, teicoplanin MIC data were not available for all isolates.
Although we cannot exclude reduced susceptibility as a potential
cause of some cases of OPAT failure, our definition was not
restricted to microbiological relapse or infection progression,
but more broadly reflected a failure of OPAT. There was only
one observed episode of microbiological relapse during OPAT in
patients who received teicoplanin (the emergence of a small
variant-colony Staphylococcus in a patient with PVE), although
readmission with IE decompensation, which could reflect anti-
biotic failure, was observed in 7/18 courses. In agreement with
these findings, glycopeptides were linked to increased readmis-
sions in a retrospective OPAT IE study, although whether this
association was independent of confounding factors such as or-
ganism or valve type was not tested.4
The rate of readmission we observed (26.3%) was consistent
with other studies (range 10%–53%),3 – 7 and our data generally
support the conclusion of recent European guidelines that
patients with high-risk features can be managed using OPAT.2 Al-
though PVE was associated with failure in univariate analysis, the
association was lost when adjusting for other confounding
factors. This was also the case for several other established high-
risk features from inpatient datasets.1
There are several limitations to these data. Although pro-
spectively recorded, they were not collected in the context of a
clinical trial. Follow-up data were obtained by retrospective ana-
lysis and therefore incompleteness of data cannot be entirely
excluded. This is the largest UK OPAT IE cohort involving
.12 years of data, and compares favourably in size to other ob-
servational studies,3 – 7 yet the number of episodes was relatively
small, and larger multicentre prospective studies are needed.
Although we comprehensively analysed factors reported to influ-
ence outcome,1 we cannot exclude the possibility that unknown
confounding factors that were not recorded may have influenced
the findings. Unlike other observational studies,3 – 7 where the
treating clinician subjectively judged clinical success, we used a
conservative composite endpoint for OPAT failure that almost
certainly overestimated the apparent rate of ‘failure’ in our
cohort compared with other studies. However, this composite
endpoint captured the important adverse outcomes associated
with OPAT and predicted ADO, suggesting it is an appropriate
standard by which to objectively measure OPAT performance.13
In summary, using a conservative definition of OPAT failure, we
observed that patients with pre-existing cardiac and renal
dysfunction were more likely to fail to complete a planned OPAT
treatment course. Thus, in our experience, these comorbid condi-
tions represent a relative contraindication to OPAT participation.
Similarly, teicoplanin was associated with an increased risk of
OPAT failure, despite adequate dosing and predominantly due to
either IE decompensation or adverse events. Alternative regimens
to teicoplanin in the OPAT setting should be further investigated.
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